Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine source : Www.biospace.com save search
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | News | $0.87 -7.05% -7.59% 350K
|
n/a
|
| O: -7.45%
H: 0.0%
C: 0.0%
hepatitis vaccine license granted biopharma virus trial
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Published: 2024-04-04 (Crawled : 12:30) - biospace.com/
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 2.79%
H: 2.03%
C: 0.34%
vaccine influenza collaboration program
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
VBIV | $0.6001 -1.46% -1.48% 180K
|
Health Technology
| Email alert
Add to watchlist
partnership vaccine platform
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
EVAX | $4.21 2.43% 2.38% 35K
|
Manufacturing
|
| O: 6.58%
H: 14.71%
C: 14.12%
vaccine infection results
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Published: 2024-03-27 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 2.02%
H: 1.41%
C: 0.92%
vaccine trials
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -3.93%
covid-19 vaccine positive trial results
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.0%
H: 0.68%
C: 0.63%
pneumococcal vaccine merck positive
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
CVM | $1.5 1.33% 160K
|
Health Technology
|
| O: 0.0%
H: 1.46%
C: -0.98%
vaccine treat immunology
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.41%
H: 0.04%
C: -0.81%
gardasil vaccine merck trials
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
ANIX | News | $3.09 1.31% 1.29% 59K
|
Health Technology
|
| O: -1.23%
H: 2.18%
C: 0.62%
vaccine congress world presentation
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.47%
C: 0.2%
vaccine dengue tak-003 qdenga
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
Published: 2024-02-21 (Crawled : 15:00) - biospace.com/
IBRX | $4.92 -6.11% -6.5% 3.5M
|
Manufacturing
|
| O: 1.27%
H: 0.31%
C: -2.3%
first vaccine cancer trial
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - February 5, 2024
Published: 2024-02-05 (Crawled : 14:30) - biospace.com/
ARCT 4 | $26.31 -4.81% -5.06% 610K
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
Published: 2024-01-23 (Crawled : 13:30) - biospace.com/
ANIX | News | $3.09 1.31% 1.29% 59K
|
Health Technology
|
| O: 0.0%
H: 3.09%
C: 1.03%
patent vaccine cancer technology
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Published: 2024-01-05 (Crawled : 13:30) - biospace.com/
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 0.71%
H: 4.24%
C: 2.12%
covid-19 vaccine positive collaboration program technology platform
Fluzone High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza
Published: 2024-01-03 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: -0.26%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.38%
H: 0.0%
C: 0.0%
vaccine influenza
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
Published: 2023-12-12 (Crawled : 15:30) - biospace.com/
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 5.03%
H: 0.0%
C: -3.82%
ICVX | $15.31 -0.65% 9.3M
|
|
| O: 53.48%
H: 1.02%
C: 0.26%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 1.54%
H: 0.06%
C: -0.78%
vaccine astrazeneca positive acquire rsv potential
AstriVax Awarded €3 Million Grant to Advance therapeutic Hepatitis B Vaccine
Published: 2023-12-12 (Crawled : 07:00) - biospace.com/
BNPQY | $34.25 -2.68% 180K
|
Finance and Insurance
|
| O: -0.3%
H: 0.12%
C: 0.03%
hepatitis vaccine grant
GSK Pulls Ahead of Pfizer in RSV Vaccine Market as Arexvy Nears Blockbuster S...
Published: 2023-12-01 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: -0.05%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
vaccine rsv market
GSK Pulls Ahead of Pfizer in RSV Vaccine Market as Arexvy Nears Blockbuster Status
Published: 2023-12-01 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: -0.05%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
vaccine rsv market
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.